Continuous HRT with oestrogen plus progestogen is linked to reduced risk of endometrial cancerBMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h6627 (Published 08 December 2015) Cite this as: BMJ 2015;351:h6627
- Susan Mayor
Continuous hormone replacement therapy (HRT) with combined oestrogen plus progestogen significantly reduced the risk of endometrial cancer in postmenopausal women, a large randomised US study has shown.1
The Women’s Health Initiative study, reported in the Journal of the National Cancer Institute, randomised 16 608 women aged 50-79 to once daily HRT (conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate as a single pill) or matching placebo for a median …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial